LTX-109 for behandling av infiserte diabetes fotsår

The main deliverable of the CureDFI project is to provide evidence that there is a potential clinical efficacy of LTX-109 in treating mild infected diabetic foot ulcers. This will be done through the data generated in a clinical Phase 2 trial which will comprise the main Work Package. This clinical trial will aim to find the effective and safe dose of LTX-109 to treat mildly infected diabetic foot ulcers in addition to prove the efficacy of LTX-109 as treatment in mild infected diabetic foot ulcers over placebo.

There will also be negotiations and consultations with European and US regulatory agencies in order to agree a clinical road-map for the pivotal Phase 3 studies.

This project is a collaboration between four SME partners to jointly delivering a successful result through a proof-of-concept clinical Phase 2 study. A successful result of the project would also facilitate attraction of potential pharma partners to take the drug through rigorous global Phase 3 trials.